Related Experiment Videos
Human response to a malaria vaccine candidate antigen
1Malaria Research Centre, Delhi, India.
Vaccine
|July 1, 1991
Summary
The Plasmodium falciparum heat-shock protein 70 (PFHSP70) shows limited immune response in malaria patients, making it a poor candidate for a malaria vaccine. Most individuals did not develop antibodies against PFHSP70 during infection or recovery.
Area of Science:
- Immunology
- Parasitology
- Vaccine Development
Background:
- The Plasmodium falciparum heat-shock protein 70 (PFHSP70) is a potential malaria vaccine antigen.
- Evaluating the human immune response to PFHSP70 is crucial for vaccine development.
Purpose of the Study:
- To assess the human immune response to PFHSP70 in individuals with and recovering from malaria.
- To determine the suitability of PFHSP70 as a malaria vaccine candidate antigen.
Main Methods:
- Serum samples from malaria patients and recovered individuals were analyzed.
- Enzyme-linked immunosorbent assays (ELISA) were used to detect antibodies against PFHSP70.
Main Results:
- Only 70% of falciparum malaria patients responded to PFHSP70 during infection.
- 54% of recovered individuals lacked detectable PFHSP70 antibodies.
- Non-responsiveness was not linked to age, sex, or region and did not correlate with responses to total schizont antigens.
Conclusions:
- PFHSP70 elicits a weak and inconsistent immune response in humans.
- The observed immune response profile makes PFHSP70 an unsuitable candidate for a malaria vaccine.